<SEC-DOCUMENT>0001193125-21-087749.txt : 20210506
<SEC-HEADER>0001193125-21-087749.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210319172959
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-21-087749
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Reneo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001637715
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472309515
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		P.O. BOX 675614
		CITY:			RANCHO SANTA FE
		STATE:			CA
		ZIP:			92067
		BUSINESS PHONE:		619-733-3852

	MAIL ADDRESS:	
		STREET 1:		P.O. BOX 675614
		CITY:			RANCHO SANTA FE
		STATE:			CA
		ZIP:			92067
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g111603g0319145543264.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason Kent</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (858) <FONT
STYLE="white-space:nowrap">550-6044</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">jkent@cooley.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">Via EDGAR and Courier</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 19, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities
and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Tracey Houser </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Kevin Kuhar </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Kasey Robinson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Suzanne Hayes </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <B>Reneo Pharmaceuticals,
Inc.</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Submitted February&nbsp;12, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CIK No.&nbsp;0001637715 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of Reneo Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;), we submit this letter in response to comments received from
the staff (the &#147;<B><I>Staff</I></B>&#148;) of the U.S. Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) by letter dated March&nbsp;12, 2021 (the &#147;<B><I>Comment Letter</I></B>&#148;) with respect to the
Company&#146;s draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> confidentially submitted to the Commission on February&nbsp;12, 2021. Concurrently with the submission of this response letter, the Company is filing an
amended version of its Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) with the Commission. In addition to addressing the comments raised by the Staff in the Comment
Letter, the Company has included other revisions and updates to its disclosure in the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the convenience of the Staff, the
numbering of the paragraphs below corresponds to the numbering of the comment in the Comment Letter, the text of which we have incorporated into this response letter for convenience in italicized type and which is followed by the Company&#146;s
response. Page references in the text of this response letter correspond to the page numbers of the Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prospectus Summary, page 1
</U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note references to early clinical data and preliminary results that treatment with REN001 produced
outcomes that are &#147;substantially more than what would be expected in patients receiving a placebo,&#148; &#147;consistent with the potential of REN001 to provide what is considered meaningful clinical improvement&#148; and similar statements
indicating findings of efficacy. Please revise to remove any statements that suggest the efficacy of your product candidate, as these determinations are the exclusive authority of the FDA or other regulators. Also, please limit the prospectus
summary discussion of trial results to an objective description of the endpoints of your trials and whether they were met. For example, rather than stating that treatment with REN001 &#147;improved exercise performance and increased oxygen
consumption and stamina, as well as improved patient reported symptoms,&#148; present your trial</I><I></I><I>&nbsp;observations without concluding that REN001 caused the observations.</I><I></I><I>&nbsp;To the extent your involved participants
received a placebo, you may contrast the objective results with the objective results of participants receiving a placebo.</I><I></I><I>&nbsp;If your trial did not involve any participants receiving a placebo, it is not appropriate to compare the
results to your expectations of what the results you would expect from participants receiving a placebo.</I><I></I><I>&nbsp;Similarly revise the disclosure throughout your filing.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;101 California Street, 5th Floor&nbsp;&nbsp;&nbsp;&nbsp;San Francisco, CA&nbsp;&nbsp;&nbsp;&nbsp;94111-5800
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (415) <FONT STYLE="white-space:nowrap">693-2000</FONT> f: (415) <FONT STYLE="white-space:nowrap">693-2222</FONT> cooley.com </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g111603g0319145543264.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 19, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the
disclosure on pages&nbsp;1, 3, 85, 97 and 98 to remove statements that present a conclusion regarding the efficacy of its product candidates and to limit the discussion of clinical trial results to an objective description of the clinical trial
endpoints and whether they were met. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise the last item in your pipeline table to identify the indication or tell us why you believe
this item is sufficiently material to warrant inclusion in the table despite not having identified an indication.</I><I></I><I>&nbsp;The lack of information and the indication that you will select your next program in 2022 or later appears to
indicate that this is not currently material and does not warrant disclosure in the summary.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In
response to the Staff&#146;s comment, the Company has revised the pipeline table on pages&nbsp;2 and 97 of the Registration Statement to remove the previously included last item. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Our Strategy, page 3 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise to delete your intention to &#147;rapidly&#148; develop and &#147;successfully&#148;
commercialize REN001. </I><I></I><I>Given the length of time it takes to conduct clinical trials and the frequency with which clinical trials fail to meet trial endpoints, any indications that you will be able to perform them rapidly appears
inappropriate.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on
pages&nbsp;3, 4, 99 and 100 of the Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Use of Proceeds, page 75 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise your disclosure to separately disclose the amount of proceeds to be
allocated</I><I></I><I>&nbsp;to fund the research and development of REN001 in <FONT STYLE="white-space:nowrap">LC-FAOD</FONT> and McArdle disease, respectively.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on page&nbsp;76 of the Registration Statement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Dilution, page 79 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please include a table comparing the public contribution under the proposed public offering and the
effective cash cost to officers, directors, promoters and affiliated persons of common equity acquired by them in transactions since inception.</I><I></I><I>&nbsp;Include columns for the number and percent of shares purchased; amount and percent of
total consideration; and the average price per share for existing shareholders versus new investors.</I><I></I><I>&nbsp;Refer to Item 506 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 101 California
Street, 5th Floor San Francisco, CA 94111-5800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (415) 693-2000 f: (415) 693-2222 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g111603g0319145543264.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 19, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Three </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response:</B> In response to the Staff&#146;s comment, the Company has revised the
disclosure on page 81 of the Registration Statement to include the requested table which provides for comparison of the public contribution under the proposed public offering and the effective cash cost to officers, directors, promoters and
affiliated persons of common equity acquired by them in transactions since inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Business </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Phase 1b Clinical Results in PMM, page 101 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise your disclosure with respect to the Phase 1b clinical trial results discussed in this section
to disclose</I><I></I><I>&nbsp;whether the studies were powered to show statistical significance.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response:
</B>The Company respectfully advises the Staff that the REN001 Phase 1b clinical trials in PMM, <FONT STYLE="white-space:nowrap">LC-FAOD,</FONT> and McArdle disease are open-label studies and do not include a comparator (placebo group). Open-label
studies have no comparator group to calculate statistical significance against, and therefore the concept of powering to show statistical significance is not applicable. The Company has revised the disclosure on page&nbsp;105 of the Registration
Statement to clarify that the Phase 1 clinical trials are open-label. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Preclinical Results and Plans, page 108 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that</I><I></I><I>&nbsp;current FDA guidance requires sponsor companies developing
PPAR agonists to complete carcinogenicity studies prior to conducting clinical studies longer than <FONT STYLE="white-space:nowrap">6-months</FONT> in duration, and that you are</I><I></I><I>&nbsp;currently conducting the required <FONT
STYLE="white-space:nowrap">two-year</FONT> carcinogenicity studies with REN001.</I><I></I><I>&nbsp;Please expand your disclosure to explain what these studies entail and revise your development plan disclosure</I><I></I><I>&nbsp;on pages <FONT
STYLE="white-space:nowrap">105-106</FONT></I><I></I><I>&nbsp;to discuss your plans as they relate to these studies.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: In response to the Staff&#146;s comment, the Company has revised the disclosure on page&nbsp;114 of the Registration Statement
to explain what the Company&#146;s carcinogenicity studies with REN001 entail. The Company further advises the Staff the design of its clinical trials limits dosing to patients within the United States to
<FONT STYLE="white-space:nowrap">6-months</FONT> in duration in conformity with the FDA&#146;s guidance. In addition, the Company has revised the disclosure on page&nbsp;114 of the Registration Statement to discuss the Company&#146;s plans as they
relate to these carcinogenicity studies with REN001 and has included a cross reference to such disclosure in the section titled &#147;Clinical development plans in PMM&#148; on page&nbsp;109 of the Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>License Agreement with vTv Therapeutics LLC, page 111 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that your royalty obligations under the</I><I></I><I>&nbsp;vTv License Agreement
will continue</I><I></I><I>&nbsp;until the latest of (i)</I><I></I><I>&nbsp;expiration of the licensed patents covering a licensed product in a country, (ii)</I><I></I><I>&nbsp;expiration of regulatory exclusivity rights for a licensed product in a
country and (iii)</I><I></I><I>&nbsp;a specified number of years after the first commercial sale of a licensed product in a country.</I><I></I><I>&nbsp;Please revise to clarify when the patents and regulatory exclusivity rights underlying such
royalty terms are expected to expire and disclose the &#147;specified number of years&#148; after the first commercial sale of a licensed product.</I><I></I><I>&nbsp;In addition, please revise to disclose the &#147;certain development stage&#148;
that triggers different termination provisions.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 101 California
Street, 5th Floor San Francisco, CA 94111-5800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (415) 693-2000 f: (415) 693-2222 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g111603g0319145543264.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 19, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Four </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: In response to the Staff&#146;s comment, the Company has revised the
disclosure on page&nbsp;115 of the Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Intellectual Property, page 112 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that, in addition to</I><I></I><I>&nbsp;patent protection around REN001, you
also</I><I></I><I>&nbsp;have licensed from vTv Therapeutics three issued patents in the United States and 20 issued patents in foreign countries related to other PPAR agonists.</I><I></I><I>&nbsp;Please disclose the expected expiration dates of
these issued patents.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: In response to the Staff&#146;s comment, the Company has revised the
disclosure on pages&nbsp;116 and 117 of the Registration Statement to provide the expected expiration dates for the issued patents related to other PPAR agonists. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Description of Capital Stock </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Choice of Forum, page
163 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please ensure that the exclusive forum provision in your</I><I></I><I>&nbsp;amended and restated certificate
of incorporation and amended and restated bylaws</I><I></I><I>&nbsp;to be in effect upon the closing of this</I><I></I><I>&nbsp;offering</I><I></I><I>&nbsp;clearly states that this provision does not apply to actions arising under the Exchange Act,
or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Exchange Act.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully advises the Staff that the exclusive forum provision in its amended and restated certificate of
incorporation and amended and restated bylaws to be in effect upon the closing of this offering and which are filed as exhibits to the Registration Statement clearly state that the exclusive forum provision does not apply to actions arising under
the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Subsequent Events, page <FONT STYLE="white-space:nowrap">F-21</FONT> </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please expand your disclosure for the January 2021 stock options grant to include the total amount of
compensation expense associated with the grant and the period over which the expense will be recognized.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: In response to the Staff&#146;s comment, the Company has revised the disclosure on page F-22 of the Registration Statement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>General </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the
Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section</I><I></I><I>&nbsp;5(d) of the Securities Act, whether or not they retain copies of the communications.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company is providing to the Staff, on a supplemental basis, copies of the written communications,
as defined in Rule 405 under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), that have been used in meetings with potential investors in reliance on Section&nbsp;5(d) of the Securities Act. These materials were
only made available for viewing by potential investors during the Company&#146;s presentations, and no copies were retained by any potential investor. Pursuant to Rule 418 under the Securities Act, the copies supplementally provided shall not be
deemed to be filed with, or a part of, or included in, the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 101 California
Street, 5th Floor San Francisco, CA 94111-5800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (415) 693-2000 f: (415) 693-2222 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g111603g0319145543264.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 19, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Five </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To the extent the Company conducts additional meetings, it expects to use the same or similar
materials, and the Company undertakes to provide the Staff with copies of any additional written communications that are presented to potential investors in the future by it or anyone authorized to do so on its behalf in reliance on
Section&nbsp;5(d) of the Securities Act, whether or not such potential investors retain copies of such communications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 101 California
Street, 5th Floor San Francisco, CA 94111-5800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (415) 693-2000 f: (415) 693-2222 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g111603g0319145543264.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 19, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Six </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please contact me at (858) <FONT STYLE="white-space:nowrap">550-6044</FONT> or Kristin
VanderPas at (415) <FONT STYLE="white-space:nowrap">693-2097</FONT> with any questions or further comments regarding the Company&#146;s response to the Staff&#146;s comments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason Kent</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jason Kent</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cooley LLP</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gregory Flesher, Reneo Pharmaceuticals, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wendy Johnson, Reneo Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kristin VanderPas, Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brian J. Cuneo, Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Matthew T. Bush, Latham&nbsp;&amp; Watkins LLP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 101 California
Street, 5th Floor San Francisco, CA 94111-5800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (415) 693-2000 f: (415) 693-2222 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g111603g0319145543264.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111603g0319145543264.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M (D# 2(  A$! Q$!_\0
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MY[:)XF&"I45Y5X8#>'OB9/I<#DV[NT1&>HZC\JZ*\^*ND)9EK2*>6X(^5&7
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4A\'.47[\]/1=?O-RDHS16IY1_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
